Clinical Trials

Non-Muscle Invasive Bladder Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Non-Muscle Invasive Bladder Neoplasms

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03756311 2026-01-23

Expanded Access to NanoPac

GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

NCT03523338 2025-12-10

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT06090331 2025-07-08

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Carcinoma, Renal Cell

NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Approved for marketing

Metastatic Castration-resistant Prostate Cancer

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Neoplasm Metastasis, Prostatic Neoplasms

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Approved for marketing

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05494411 2025-02-28

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Temporarily not available

Carcinoma, Transitional Cell

NCT06033001 2025-01-13

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms, Castration-Resistant

NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04825652 2023-01-13

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03801278 2021-12-13

FPA144

Urinary Bladder Neoplasms

NCT04337099 2021-05-05

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Prostatic Neoplasms

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)